PharmaAcuity

?????? ???????????? ???? ???? ??????'?? ?????? - ???? ?????? ?????????? ???? ????????????????. There is a lot of both excitement and fear in our industry when it comes to AI. And everyone is trying to work out how to get started and how to help their teams on this journey. There is also this perception AI will threaten the very nature of creativity. I wholeheartedly disagree. Just like every other technology or tool that creatives have been able to work with, they will do amazing things with AI that surprise and delight us all, we are already seeing this. I get asked a lot about what leaders should do in this moment, so ahead of #Cannes next week, I shared my perspective on how to get started in a piece with Fortune Magazine.?If I’ve figured out anything in 20 years at Google, it’s that we shape technology by using it. So use it! AI tools are already available, there’s no need for advanced training or coding knowledge to take part. Here are a few things I’ve learned and how we can all embrace this moment: ??It starts at the top. As leaders, it’s on all of us to help our teams by building a culture of curiosity and experimentation, and we need to get hands-on ourselves and use these tools at work and in life. I love using AI to summarize entire email threads or give me feedback on how our creative work will be received. ??Give your teams permission to innovate. Great ideas come from anywhere. So encourage everyone in your team to try various AI tools and share their best ideas! ??There is no wrong way to experiment. Identifying a specific pain point is one way people get started. ??For many creatives, a blank page can be terrifying. So put the horror of the first terrible draft on AI. Spare yourself. Then be brilliant. Check out the piece here, and let me know how you and your teams are using AI today - we can all learn from each other! https://lnkd.in/gtZ_bBnk And if you want to get your creative juices flowing, check out our AI Essentials course to learn how to use GenAI tools in your life: https://lnkd.in/gNEthfJh #AI #Marketing #Creativity #CannesLions2024 Google

ASCO 2024 Highlight - MERUS PharmaAcuity’s congress coverage platform, PA AI, will be sharing a daily highlight from @ASCO 2024 that created interest on social media. As one of the hottest weeks in cancer science is winding down, the online world is still abuzz with chatter about the conference. One of the key areas of chatter was about Merus (Nasdaq: MRUS), a clinical-stage oncology company. Merus presented Petosemtamab interim data which showed clinically meaningful activity in previously treated head and neck squamous cell carcinoma: -?????????Merus announced Tuesday that the combination of its development stage therapeutic Petosemtamab and the checkpoint inhibitor Keytruda reduced tumor-- size in 62% of patients with head and neck cancer, based on an interim analysis of an ongoing mid-stage clinical study. Merus (MRUS) experienced a significant bump in it’s share of voice, with folks expressing enthusiasm about the data that was presented.

ASCO 2024 Highlight - MERUS PharmaAcuity’s congress coverage platform, PA AI, will be sharing a daily highlight from @ASCO 2024 that created interest on social media. As one of the hottest weeks in cancer science is winding down, the online world is still abuzz with chatter about the conference. One of the key areas of chatter was about Merus (Nasdaq: MRUS), a clinical-stage oncology company. Merus presented Petosemtamab interim data which showed clinically meaningful activity in previously treated head and neck squamous cell carcinoma: -?????????Merus announced Tuesday that the combination of its development stage therapeutic Petosemtamab and the checkpoint inhibitor Keytruda reduced tumor-- size in 62% of patients with head and neck cancer, based on an interim analysis of an ongoing mid-stage clinical study. Merus (MRUS) experienced a significant bump in it’s share of voice, with folks expressing enthusiasm about the data that was presented.